

1 **Title:** COVID-19 in Latin America: Contrasting phylodynamic inference with  
2 epidemiological surveillance.

3 **Running title:** Phylodynamic analysis of COVID-19 in Latin America

4 **Authors:** Diana M. Rojas-Gallardo,<sup>1</sup> Sandra C. Garzón-Castaño,<sup>1</sup>[1\(https://orcid.org/0000-0002-9547-](https://orcid.org/0000-0002-9547-967X)  
5 [967X\)](https://orcid.org/0000-0002-9547-967X), Natalia Millán<sup>2</sup>, Erika V. Jiménez-Posada<sup>4</sup>, (<http://orcid.org/0000-0002-3737-9427>), Jaime A.  
6 Cardona-Ospina.<sup>1,2,3,4\*</sup> (<https://orcid.org/0000-0003-3996-2293>)

7 **Affiliations:** <sup>1</sup>Grupo de Investigación Biomedicina, Facultad de Medicina, Fundación  
8 Universitaria Autónoma de las Américas, Pereira, Risaralda, Colombia. <sup>2</sup>Semillero de  
9 Investigación en Infecciones Emergentes y Medicina Tropical, SIEM, Fundación  
10 Universitaria Autónoma de las Américas, Pereira, Risaralda, Colombia, <sup>3</sup>Public Health and  
11 Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira,  
12 Pereira, Risaralda, Colombia. <sup>4</sup>Emerging Infectious Diseases and Tropical Medicine  
13 Research Group. Instituto para la Investigación en Ciencias Biomédicas - Sci-Help, Pereira,  
14 Risaralda, Colombia.<sup>5</sup>Grupo de Biotecnología-Productos Naturales, Facultad de Tecnología,  
15 Universidad Tecnológica de Pereira, Colombia

16 **\*Corresponding author:** Jaime A. Cardona-Ospina, Phone +57 311 339 5249, Fundación  
17 Universitaria Autónoma de las Américas, Bloque B, Av. de las Américas #98-56 Sector  
18 Belmonte, Pereira, Risaralda, Colombia, Postal Code: 660001, e-mail:  
19 [jaime.cardona@uam.edu.co](mailto:jaime.cardona@uam.edu.co)

20 Words: 1991 | Abstract: 308 | Figures: 3 | Tables: 1 | Supplementary Tables: 2

21

22 **Abstract:**

23 **Introduction:** SARS-CoV-2 infection has represented the one of the largest challenges for  
24 humanity. This virus was first detected in Latin America and the Caribbean (LAC) in Brazil  
25 in February 26, 2020 and it has revealed important gaps in infectious disease surveillance  
26 that must be covered. Phylodynamic analysis is a tool that can help to monitor and adapt  
27 traditional surveillance measures in order to cover those. Therefore, this work aims to  
28 contrast data driven from epidemiologic surveillance in LAC with parameters inferred from  
29 phylodynamic analysis of reported genomes of SARS-CoV-2 across different LAC  
30 countries **Methods:** We obtained epidemiological data from daily reports provided by  
31 European Centre for Disease Prevention and Control up to 13<sup>th</sup> May, 2020. We estimated  
32 Effective Reproductive Number ( $R_e$ ) and calculated epidemic curves with exponential  
33 growth (EG) and maximum likelihood (ML) methods. SARS-CoV-2 phylodynamic in  
34 Latin-American was analyzed using sequences reported in GISAID for Central and South  
35 America up to May 13<sup>th</sup> 2020. Sequences were aligned, and ML phylogeny was  
36 constructed. Coalescent model Birth Death SIR (serial) was run, and SIR trajectories from  
37 the birth-death SIR model were plotted. **Results:** A total of 404,448 cases were reported up  
38 to 13<sup>th</sup> May 2020. Overall reproduction number for Latin America, estimated through the  
39 EG and ML methods, were 1.424 (IC95% 1.422 to 1.426) and 1.305 (IC95% 1.299 to  
40 1.311) respectively. Phylodynamic analysis for Latin America showed an overall  $R_e$  of  
41 1.27 (IC95% 1.07 to 1.49). We did not find statistically significant differences between  
42 epidemiological and phylodynamic data at the cut-off time, except for Brazil. **Discussion:**  
43 Our results support that epidemiological and genomic surveillance are two complementary  
44 approaches. Evidence suggests that even with a low number of sequences proper  
45 estimations of  $R_e$  could be performed. We suggest that countries, especially developing

46 countries, should consider to add genomic surveillance to their systems for monitoring and  
47 adapting epidemiological surveillance of SARS-CoV-2.

48

49 **Keywords:**

50 SARS-CoV-2, COVID-19, Phylodynamic, Epidemiology, Latin America

51

52 **Introduction:**

53

54 SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus - 2) infection, called  
55 COVID-19, has represented one of the largest challenge for humanity, and has revealed the  
56 need for better, more accurate, and more expedite surveillance tools, for improving  
57 infectious disease control. SARS-CoV-2 transmissibility across the world has varied  
58 widely<sup>1</sup>, apparently related with control measures, and intensity of disease surveillance.  
59 COVID-19 has revealed deep gaps in our society derived from social inequalities, and has  
60 showed the importance of solid evidence based decision making, the need to strength our  
61 healthcare systems and to improve infectious disease surveillance.

62

63 After the emergence of SARS-CoV-2 in Wuhan, central China in December 2019, COVID-  
64 19 rapidly spread across the world, and was first reported in Latin America and the  
65 Caribbean (LAC) on February 26, 2020 in Brazil<sup>1</sup>. This virus belongs to the genus  
66 Betacoronavirus of the Coronaviridae family, it has a (+) ssRNA genome of approximately  
67 29,903bp, and the genomic information accumulated through its evolution has been used  
68 for tracking its molecular relatedness with other coronaviruses, and for estimating  
69 transmission networks, epidemic size, and effective reproduction number (Re)<sup>2-5</sup>.

70

71 In this context, current available phylogenetic methods can serve as tool for improving  
72 infectious disease surveillance. Development of the coalescent theory allows to infer from  
73 evolutionary analysis the epidemiologic behavior of a pathogen, especial those rapidly  
74 evolving, like RNA virus<sup>6-8</sup>. These analysis can enhance disease surveillance efforts,  
75 provide additional data for adapting disease surveillance strategies, and can help to assess

76 effectiveness of implemented surveillance as well as to estimate the  $R_e$ , generation time,  
77 and epidemic size<sup>9,10</sup>. This work aims to contrast data driven from epidemiologic  
78 surveillance in LAC with parameters inferred from phylodynamic analysis of reported  
79 genomes of SARS-CoV-2 across different LAC countries.

80

## 81 **Materials and Methods**

82

### 83 **Epidemiological data source**

84

85 In order to contrast phylodynamic inference with COVID-19 epidemiological surveillance  
86 data, we obtained data published by the European Centre for Disease Prevention and Control  
87<sup>1</sup> until 13<sup>th</sup> May, 2020. Countries were filtered by continent and only countries belonging to  
88 Latin America and the Caribbean region were included. Incident cases and dates of reporting  
89 were obtained, as well as fatal cases. We calculated Case Fatality Rates (CFR) = number of  
90 reported deaths/number of total cases) X 100, and estimated  $R_e$  and epidemiologic curves  
91 using exponential growth and maximum likelihood methods<sup>11-13</sup>.

92

### 93 **Estimation of Effective Reproduction Numbers**

94

95 In order to estimate  $R_e$ , we estimated the Generation time (GT) using the R package  $R_0$ <sup>11</sup>.  
96 The distribution of the generation time, considered as the time between a primary infected  
97 case and a secondary case, was estimated by Maximum Likelihood using the serial time  
98 between infectee/infectors pairs published by He et al, 2020<sup>11,14</sup>. Then,  $R_e$  at the beginning  
99 of the epidemic, and its evolution through time were estimated using Exponential Growth

100 (EG) and Maximum Likelihood (ML) methods<sup>12, 13, 15</sup>. The time period over which growth  
101 is exponential was estimated using the deviance R-squared statistic over a range of possible  
102 time periods<sup>11</sup>.

103

#### 104 **Dataset for phylodynamic analysis**

105

106 In order to investigate de SARS-CoV-2 phylodynamic in Latin-American, we search for  
107 sequences reported in GISAID<sup>16</sup> for Central and South America up to May 13<sup>th</sup> 2020. We  
108 choose only whole genome sequences (>29,900) of the virus with high coverage, and more  
109 than 95% of nucleotide base resolved. We conserved identical sequences with different  
110 sampling dates and different location and discard identical sequences with same sampling  
111 date between countries. Accession IDs, sampling dates and locations of the sequences were  
112 obtained, as well as clinical metadata when available. We also generated subgroup datasets  
113 for each country reporting at least five sequences.

114

#### 115 **Phylogenetic analyses**

116

117 Sequences were aligned using MAFFT software v7.450<sup>17</sup> and visually inspected and edited  
118 using Bioedit v7.0.5.3. To assess the recombination for the dataset, we employed the  
119 pairwise homoplasy index (PHI) test using SplitsTree v4.15.1<sup>18</sup>. Nucleotide substitution  
120 model for the alignment was inferred according to the corrected Akaike information  
121 criterion (AICc) in jModelTest v2.1.10<sup>19</sup>. Maximun Likelihood (ML) phylogeny was  
122 constructed using PhyML software v3.1<sup>20</sup> and the tree was visualized and edited with  
123 FigTree software v1.8.

124

## 125 **Coalescent analyses**

126

127 For LAC and each country data set, coalescent model Birth Death SIR (serial) <sup>21</sup> was run  
128 with *Phylodynamics* package in BEAST v2.6.2.0 <sup>22</sup>. Priors were introduced with BEAUti  
129 and all data sets were run with the same prior distribution and value for Molecular clock  
130 rate (1.0 (estimated)), Become Uninfectious Rate (Normal (mean=37.0, sigma =1.3)) and  
131 Reproductive Number (Log-normal (mean log=0,0, sd log =1.2)). Markov chain Monte  
132 Carlo (MCMC) runs of 80 million states sampling every 8,000 steps were computed. The  
133 convergence of MCMC chains was checked using Tracer v.1.7.1<sup>23</sup>, ensuring that the  
134 effective sample size (ESS) values were greater than 300 for each parameter estimated. For  
135 LAC data set, the maximum clade credibility (MCC) trees were obtained from the tree  
136 posterior distribution using TreeAnnotator after 10% burn-in <sup>23</sup>. To plot SIR trajectories  
137 from the birth-death SIR model we used NELSI package for R.

138

## 139 **Sensitivity analysis**

140

141 We conducted a sensitivity analysis computing the R-squared statistic over a  
142 range of possible time periods for exponential growth (begin between days 1 to 39, and  
143 ending between days 40 to 79), selecting the best fit for EG and ML analysis. In order to  
144 assess the effect of GT distribution variation on Re estimation, we computed the  
145 reproduction ratio over a range of chosen generation time distributions with mean between  
146 1 to 14 days, assuming fixed standard deviation, and using ML method.

147

148 **Results**

149

150 A total of 404,448 cases were reported up to 13<sup>th</sup> May 2020, with 23,153 deaths (overall  
151 CFR 5.72%). The countries with most cases were: Brazil (177,589 cases), Peru (72,059  
152 cases), Mexico (38,324 cases), Chile (31,721 cases) and Ecuador (30,419 cases), while the  
153 countries with the highest CFR were Saint Maarten (19.48%), British Virgin Islands  
154 (14.29%), Antigua and Barbuda (12%), Bahamas (11.83%) and Belize (11.11%), Table 1.

155 A total of 124 genomic sequences were retrieved from GISAID library <sup>16</sup>, and after quality  
156 clearance 76 genomic sequences, from 6 countries, were finally included for analysis  
157 (**Supplementary Table 1**).

158

159 Overall reproduction number for Latin America, estimated through the EG and ML  
160 methods, were 1.424 (IC95% 1.422 to 1.426) and 1.305 (IC95% 1.299 to 1.311)  
161 respectively. The epidemic curve and time dependent analysis is showed in Figure 1. The  
162 portion of the epidemic curve that best fitted exponential growth was estimated between  
163 2020-02-26 and 2020-04-11 (first 45 days), with a Growth Rate of 11.91%, and a Re of  
164 1.95 (IC95% 1.94 to 1.95) and 1.74351(IC95% 1.72 to 1.77) through EG and ML method,  
165 respectively. Sensitivity analysis showed that Re remained within the 95%IC only for a  
166 small choice of time windows Figure 1c, and that varied significantly across different GT  
167 distributions (data not shown).

168

169 For Latin American ML phylogenetic reconstruction, the GTR+I+G was the best model of  
170 nucleotide substitution for the data set (substitution rates for every data set is showed in  
171 **Supplementary Table 2**). The PHI test did not found statistically significant evidence for



172 recombination ( $p = 0.01381$ ). The ML tree (Figure 2) shown a star-like topology in which  
173 the external arms are longer than the internal without evidence of structure or space related  
174 distribution. Phylodynamic analysis for Latin America showed an overall  $Re$  of 1.27  
175 (IC95% 1.07 to 1.49).

176

177 To properly contrast observed epidemiologic curves with phylodynamic inferences, we  
178 performed subgroup analysis including only countries with at least five reported genomic  
179 sequences, and estimating epidemiological observed  $Re$  up to the date of the last available  
180 genomic sequence. Therefore, only four countries were finally included in the subgroup  
181 analysis; Brazil (last reported sequence 03-26-2020, 30 days since first case notification),  
182 Argentina (last reported sequence 04-19-2020, 44 days since first case notification), Chile  
183 (last reported sequence 03-08-2020, 5 days after first case notification) and Costa Rica (last  
184 reported sequence 03-25-2020, 18 days after first case notification). Epidemic curves and  
185 SIR trajectories for each country are showed in Figure 3.

186

187 Posterior summary of epidemiological and evolutionary parameters are shown in Table 1.  
188 When contrasting observed and inferred  $Re$ , we did not find statistically significant  
189 differences between epidemiological and phylodynamic data at the cut-off time, except for  
190 Brazil. Phylodynamic inference showed an  $Re$  for Argentina of 1.48 (IC95% 1.19 to 1.79)  
191 contrasted with epidemiological  $Re$  estimated using EG of 1.39 (IC95% 1.36 to 1.41) and  
192 ML of 1.29 (IC95% 1.22 to 1.36). For Brazil showed a  $Re$  of 1.59 (IC95% 1.18 to 2.03)  
193 contrasted with epidemiological  $Re$  estimated using EG of 3.03 (IC95% 2.92 to 3.15) and  
194 ML of 2.51 (IC95% 2.37 to 2.65). For Costa Rica showed an  $Re$  of 2.33 (IC95% 1.02 to  
195 3.78) contrasted with epidemiological  $Re$  estimated using EG of 2.14 (IC95% 1.84 to 2.48)

196 and ML of 2.09 (IC95% 1.69 to 2.56). And for Chile showed 2.69 (IC95% 1.15 to 4.41)  
197 contrasted with epidemiological Re estimated using EG of 0.02 (IC95% 0.00 to 4.51) and  
198 ML of 2.87 (IC95% 0.48 to 8.86). Additionally, we found important differences in the  
199 number of reported versus inferred prevalent cases. Phylodynamic analysis showed a total  
200 of 119 cases in Brazil, 245 cases in Argentina, 58 in Chile, and 61 cases in Costa Rica,  
201 contrasted with a total of 2,433; 2,828; 5; 177 cases reported in each country respectively,  
202 at the time of cut-off.

203

#### 204 **Discussion:**

205

206 Our results revealed an overall agreement between epidemiological observed data and  
207 photodynamically inferred Re, even for Costa Rica with only five reported genomic  
208 sequences up to the date of cut off. However, observed and inferred Re for Brazil varied  
209 widely among methods. Sensitivity analysis revealed that for obtention of overlapping Re  
210 IC95%, GT mean should be between 4.29 and 5.62 (SD range between 4.12 and 7.02),  
211 hence suggesting that likely transmission dynamics in this country could be different to  
212 those previously reported<sup>14</sup>, while the fact that observed and inferred Re were not different  
213 among the other countries supports that transmission dynamics are similar to those reported  
214 by He et al, 2020<sup>14</sup>.

215

216 However, SIR trajectories revealed disagreement in terms of incident cases, total cases and  
217 recovered cases. For some countries, recovered cases were higher than incident cases, like  
218 for example Argentina and Brazil (Figure 3). We hypothesize that this disagreement could  
219 be related with the real origin of the sequences reported from each country and the real date

220 of SARS-CoV-2 introduction. Since most of sequences available when the analysis was  
221 performed were reported at the beginning of the epidemic in each country, it is possible that  
222 genomic data did not reveal internal transmission networks but external transmission  
223 networks from imported cases. This could be supported on the analysis of ML phylogenetic  
224 tree, which did not reveal a space related distribution.

225

226 Moreover, SIR trajectories analysis for some countries inferred recovered cases above  
227 infected cases. This disagreement with the observed epidemiological data is interpreted by  
228 our group as a likely introduction before the epidemiological reported date. In order to  
229 support this hypothesis, we are currently performing Time to Most Recent Ancestor  
230 Analysis (TMRA) for each country, including new reported sequences for LAC, which up  
231 to May 22, 2020 have increased to 326 (complete and with high coverage).

232

233 Finally, our results support that epidemiological and genomic surveillance are two  
234 complementary approaches for analysis of transmission and epidemiological patterns.  
235 Overall  $R_e$  estimation for LAC through phylodynamic analysis showed good agreement  
236 with observed  $R_e$  through epidemiological surveillance even when sequences were not  
237 available from every country. Evidence suggests that even with a low number of sequences,  
238 proper estimations of  $R_e$  could be performed. This could provide important insights,  
239 especially at the beginning of an epidemic when epidemiological surveillance systems are  
240 adjusting follow-up and control measures. At the same time, we found that the lack of  
241 clinical and epidemiological metadata for reported sequences difficult making  
242 phylodynamic inferences. We suggest that countries, especially developing countries,

243 should consider to add genomic surveillance to their systems for monitoring and adapting  
244 epidemiological surveillance of SARS-CoV-2.

245

246 **Acknowledgements:**

247 We would like to acknowledge Grupo de Investigación SIRIUS, Facultad de Ingenierías,  
248 Universidad Tecnológica de Pereira, for providing resources for performing high  
249 performance computational analysis. We also want to acknowledge the laboratories that  
250 have contributed publicly available genomes via GISAID in Latin America.

251

252 **References**


253

- 254 1. European Centre for Disease Prevention and Control. Geographic distribution of  
255 COVID-19 cases worldwide. European Centre for Disease Prevention and Control,, 2020.
- 256 2. Benvenuto D, Giovanetti M, Salemi M, Prosperi M, De Flora C, Junior Alcantara  
257 LC, et al. The global spread of 2019-nCoV: a molecular evolutionary analysis. *Pathog Glob*  
258 *Health* 2020; 114:64-7.
- 259 3. Dellicour S, Durkin K, Hong SL, Vanmechelen B, Martí-Carreras J, Gill MS, et al.  
260 A phylodynamic workflow to rapidly gain insights into the dispersal history and dynamics  
261 of SARS-CoV-2 lineages. *bioRxiv* 2020.
- 262 4. Li J, Li Z, Cui X, Wu C. Bayesian phylodynamic inference on the temporal  
263 evolution and global transmission of SARS-CoV-2. *J Infect* 2020.
- 264 5. Scire J, Vaughan TG, Stadler T. Phylodynamic analyses based on 93 genomes.  
265 2020.
- 266 6. Holmes EC. Evolutionary history and phylogeography of human viruses. *Annu Rev*  
267 *Microbiol* 2008; 62:307-28.
- 268 7. Pybus OG, Rambaut A, Harvey PH. An integrated framework for the inference of  
269 viral population history from reconstructed genealogies. *Genetics* 2000; 155:1429-37.
- 270 8. Volz EM, Koelle K, Bedford T. Viral phylodynamics. *PLoS Comput Biol* 2013;  
271 9:e1002947.
- 272 9. Grenfell BT, Pybus OG, Gog JR, Wood JL, Daly JM, Mumford JA, et al. Unifying  
273 the epidemiological and evolutionary dynamics of pathogens. *Science* 2004; 303:327-32.

- 274 10. Rife BD, Mavian C, Chen X, Ciccozzi M, Salemi M, Min J, et al. Phylodynamic  
275 applications in 21(st) century global infectious disease research. *Glob Health Res Policy*  
276 2017; 2:13-.
- 277 11. Obadia T, Haneef R, Boelle PY. The R0 package: a toolbox to estimate  
278 reproduction numbers for epidemic outbreaks. *BMC Med Inform Decis Mak* 2012; 12:147.
- 279 12. Wallinga J, Lipsitch M. How generation intervals shape the relationship between  
280 growth rates and reproductive numbers. *Proc Biol Sci* 2007; 274:599-604.
- 281 13. White LF, Pagano M. A likelihood-based method for real-time estimation of the  
282 serial interval and reproductive number of an epidemic. *Stat Med* 2008; 27:2999-3016.
- 283 14. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral  
284 shedding and transmissibility of COVID-19. *Nat Med* 2020; 26:672-5.
- 285 15. Wallinga J, Teunis P. Different epidemic curves for severe acute respiratory  
286 syndrome reveal similar impacts of control measures. *Am J Epidemiol* 2004; 160:509-16.
- 287 16. Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID's innovative  
288 contribution to global health. *Glob Chall* 2017; 1:33-46.
- 289 17. Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7:  
290 improvements in performance and usability. *Mol Biol Evol* 2013; 30:772-80.
- 291 18. Huson DH, Bryant D. Application of phylogenetic networks in evolutionary studies.  
292 *Mol Biol Evol* 2006; 23:254-67.
- 293 19. Darriba D, Taboada GL, Doallo R, Posada D. jModelTest 2: more models, new  
294 heuristics and parallel computing. *Nat Methods* 2012; 9:772.
- 295 20. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. New  
296 algorithms and methods to estimate maximum-likelihood phylogenies: assessing the  
297 performance of PhyML 3.0. *Syst Biol* 2010; 59:307-21.

- 298 21. Kuhnert D, Stadler T, Vaughan TG, Drummond AJ. Simultaneous reconstruction of  
299 evolutionary history and epidemiological dynamics from viral sequences with the birth-  
300 death SIR model. *J R Soc Interface* 2014; 11:20131106.
- 301 22. Bouckaert R, Vaughan TG, Barido-Sottani J, Duchêne S, Fourment M,  
302 Gavryushkina A, et al. BEAST 2.5: An advanced software platform for Bayesian  
303 evolutionary analysis. *PLoS computational biology* 2019; 15:e1006650.
- 304 23. Rambaut A, Drummond AJ, Xie D, Baele G, Suchard MA. Posterior Summarization  
305 in Bayesian Phylogenetics Using Tracer 1.7. *Syst Biol* 2018; 67:901-4.
- 306
- 307

308 **Figure 1.** Maximum likelihood phylogenetic relationships between sequences of Latin  
309 America data set. Branch lengths estimated as nucleotide substitutions per site.  
310



328

329


330

331

332



333



342 Figure 2. Epidemic curve (A), Time-dependent analysis of  $R_e$  (B) in Latin America up to

343 May 13<sup>th</sup>, 2020, and Sensitivity analysis of exponential growth of epidemic curve (C).

344

345 Figure 3. SIR trajectories (A), and epidemic curves (B) for countries with at least five  
346 reported genomic sequences. The line corresponds to the epidemic curve estimated through  
347 ML method and the dots to incident cases up to the date of the last reported sequence.

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363


364

365

366

367

368



369 **Table 1.** Posterior summary of epidemiological and evolutionary parameters.

370

	<b>Molecular clock rate</b>	<b>95% HPD</b>	<b>Become Uninfectious Rate</b>	<b>95% HPD</b>	<b>Reproductive Number</b>	<b>95% HPD</b>
<b>Latin America</b>	0.00014	0.00011-0.00018	36.88	34.38-39.39	1.22	1.0446-1.4156
<b>Argentina</b>	0.00013	0.0006-0.002	36.86	34.25-39.25	1.48	1.022-3.78
<b>Brazil</b>	0.00028	0.00018-0.00038	36.97	43.44-39.50	1.59	1.1792-2.0277
<b>Chile</b>	0.00044	0.00006-0.00094	36.97	34.47-39.57	2.69	1.1455-4.4077
<b>Costa Rica</b>	0.00058	0.00018-0.0010	36.93	34.49-39.58	2.32	1.022-3.78

371

372 **Supplementary Table 1.** Substitution model and parameters used to run each data set with  
 373 BEAST.  
 374

Region/Country	Model	Substitutions rates	Parameters
<b>Latin America</b>	Model = GTR+I+G	R(a) [AC] = 0.3454 R(b) [AG] = 0.8055 R(c) [AT] = 0.1965 R(d) [CG] = 0.3182 R(e) [CT] = 2.6714 R(f) [GT] = 1.0000	p-inv = 0.8980 gamma category count = 0 Frequencies = empirical
<b>Argentina</b>	Model = GTR+I	R(a) [AC] = 0.0100 R(b) [AG] = 1.4896 R(c) [AT] = 0.0829 R(d) [CG] = 0.4389 R(e) [CT] = 3.9014 R(f) [GT] = 1.0000	p-inv = 0.7800 gamma category count = 0 Frequencies = empirical
<b>Brazil</b>	Model = GTR+I+G	R(a) [AC] = 0.5540 R(b) [AG] = 0.7814 R(c) [AT] = 0.2557 R(d) [CG] = 0.4662 R(e) [CT] = 2.6314 R(f) [GT] = 1.0000	p-inv = 0.9540 gamma category count = 0 Frequencies = empirical
<b>Chile</b>	GTR	R(a) [AC] = 0.0216 R(b) [AG] = 0.9991 R(c) [AT] = 0.2091 R(d) [CG] = 0.5565 R(e) [CT] = 3.7915 R(f) [GT] = 1.0000	p-inv = 0.0 gamma category count = 0 Frequencies = empirical
<b>Costa Rica</b>	HKY	Estimate	kappa = estimate

375

376

377

378 **Supplementary Table 2.** Genomic sequences with dates, countries and accession ID  
 379 included for phylodynamic analysis.  
 380

<b>Accession ID</b>	<b>Sampling date</b>	<b>Country</b>
hCoV-19/Argentina/C121/2020 EPI_ISL_420600 2020-03-07	07/03/2020	<b>Argentina</b>
hCoV-19/Argentina/C1374/2020 EPI_ISL_420599 2020-03-18	18/03/2020	<b>Argentina</b>
hCoV-19/Argentina/C3013/2020 EPI_ISL_420598 2020-03-22	22/03/2020	<b>Argentina</b>
hCoV-19/Argentina/PAIS_A001/2020 EPI_ISL_430793 2020-03-01	01/03/2020	<b>Argentina</b>
hCoV-19/Argentina/PAIS_A004/2020 EPI_ISL_430796 2020-03-27	27/03/2020	<b>Argentina</b>
hCoV-19/Argentina/PAIS_A005/2020 EPI_ISL_430797 2020-03-27	27/03/2020	<b>Argentina</b>
hCoV-19/Argentina/PAIS_A006/2020 EPI_ISL_430798 2020-03-28	28/03/2020	<b>Argentina</b>
hCoV-19/Argentina/PAIS_A007/2020 EPI_ISL_430799 2020-03-30	30/03/2020	<b>Argentina</b>
hCoV-19/Argentina/PAIS_A009/2020 EPI_ISL_430801 2020-03-31	31/03/2020	<b>Argentina</b>
hCoV-19/Argentina/PAIS_A011/2020 EPI_ISL_430802 2020-03-31	31/03/2020	<b>Argentina</b>
hCoV-19/Argentina/PAIS_A012/2020 EPI_ISL_430803 2020-04-01	01/04/2020	<b>Argentina</b>
hCoV-19/Argentina/PAIS_A013/2020 EPI_ISL_430804 2020-04-01	01/04/2020	<b>Argentina</b>
hCoV-19/Argentina/PAIS_A014/2020 EPI_ISL_430805 2020-04-01	01/04/2020	<b>Argentina</b>
hCoV-19/Argentina/PAIS_A016/2020 EPI_ISL_430807 2020-04-02	02/04/2020	<b>Argentina</b>
hCoV-19/Argentina/PAIS_A017/2020 EPI_ISL_430808 2020-04-03	03/04/2020	<b>Argentina</b>
hCoV-19/Argentina/PAIS_A018/2020 EPI_ISL_430809 2020-04-04	04/04/2020	<b>Argentina</b>
hCoV-19/Argentina/PAIS_A019/2020 EPI_ISL_430810 2020-04-07	07/04/2020	<b>Argentina</b>
hCoV-19/Argentina/PAIS_A020/2020 EPI_ISL_430811 2020-04-11	11/04/2020	<b>Argentina</b>
hCoV-19/Argentina/PAIS_A021/2020 EPI_ISL_430812 2020-04-11	11/04/2020	<b>Argentina</b>
hCoV-19/Argentina/PAIS_A023/2020 EPI_ISL_430814 2020-04-17	17/04/2020	<b>Argentina</b>
hCoV-19/Argentina/PAIS_A024/2020 EPI_ISL_430815 2020-04-18	18/04/2020	<b>Argentina</b>
hCoV-19/Argentina/PAIS_A025/2020 EPI_ISL_430816 2020-04-18	18/04/2020	<b>Argentina</b>
hCoV-19/Argentina/PAIS_A026/2020 EPI_ISL_430817 2020-04-18	18/04/2020	<b>Argentina</b>
hCoV-19/Argentina/PAIS_A027/2020 EPI_ISL_430818 2020-04-19	19/04/2020	<b>Argentina</b>
hCoV-19/Brazil/SPBR-01/2020 EPI_ISL_412964 2020-02-25	25/02/2020	<b>Brazil</b>
hCoV-19/Brazil/SPBR-06/2020 EPI_ISL_414015 2020-02-29	29/02/2020	<b>Brazil</b>
hCoV-19/Brazil/SPBR-09/2020 EPI_ISL_416031 2020-03-04	04/03/2020	<b>Brazil</b>
hCoV-19/Brazil/RJ-314/2020 EPI_ISL_414045 2020-03-04	04/03/2020	<b>Brazil</b>
hCoV-19/Brazil/CV42/2020 EPI_ISL_429695 2020-03-20	20/03/2020	<b>Brazil</b>
hCoV-19/Brazil/SPBR-03/2020 EPI_ISL_414014 2020-03-02	02/03/2020	<b>Brazil</b>
hCoV-19/Brazil/SPBR-04/2020 EPI_ISL_414017 2020-03-04	04/03/2020	<b>Brazil</b>
hCoV-19/Brazil/SPBR-07/2020 EPI_ISL_416028 2020-03-03	03/03/2020	<b>Brazil</b>
hCoV-19/Brazil/RJ-477/2020 EPI_ISL_427300 2020-03-11	11/03/2020	<b>Brazil</b>
hCoV-19/Brazil/RJ-477i/2020 EPI_ISL_427301 2020-03-11	11/03/2020	<b>Brazil</b>
hCoV-19/Brazil/DFBR-0001/2020 EPI_ISL_426580 2020-03-1	13/03/2020	<b>Brazil</b>
hCoV-19/Brazil/SPBR-08/2020 EPI_ISL_416029 2020-03-04	04/03/2020	<b>Brazil</b>
hCoV-19/Brazil/SPBR-13/2020 EPI_ISL_416035 2020-03-05	05/03/2020	<b>Brazil</b>
hCoV-19/Brazil/BA-510/2020 EPI_ISL_427293 2020-03-06	06/03/2020	<b>Brazil</b>

---

hCoV-19/Brazil/SPBR-12/2020 EPI_ISL_416034 2020-03-04	04/03/2020	<b>Brazil</b>
hCoV-19/Brazil/DF-615i/2020 EPI_ISL_427294 2020-03-13	13/03/2020	<b>Brazil</b>
hCoV-19/Brazil/DF-862/2020 EPI_ISL_427297 2020-03-23	23/03/2020	<b>Brazil</b>
hCoV-19/Brazil/DF-891/2020 EPI_ISL_427298 2020-03-22	22/03/2020	<b>Brazil</b>
hCoV-19/Brazil/RJ-763/2020 EPI_ISL_427302 2020-03-20	20/03/2020	<b>Brazil</b>
hCoV-19/Brazil/DF-861/2020 EPI_ISL_427296 2020-03-23	23/03/2020	<b>Brazil</b>
hCoV-19/Brazil/RJ-818/2020 EPI_ISL_427303 2020-03-25	25/03/2020	<b>Brazil</b>
hCoV-19/Brazil/RJ-872/2020 EPI_ISL_427304 2020-03-26	26/03/2020	<b>Brazil</b>
hCoV-19/Brazil/AL-837/2020 EPI_ISL_427292 2020-03-18	18/03/2020	<b>Brazil</b>
hCoV-19/Brazil/CV16/2020 EPI_ISL_429676 2020-03-16	16/03/2020	<b>Brazil</b>
hCoV-19/Brazil/SC-769/2020 EPI_ISL_427306 2020-03-10	10/03/2020	<b>Brazil</b>
hCoV-19/Brazil/CV4/2020 EPI_ISL_429667 2020-03-09	09/03/2020	<b>Brazil</b>
hCoV-19/Brazil/CV6/2020 EPI_ISL_429669 2020-03-13	13/03/2020	<b>Brazil</b>
hCoV-19/Brazil/CV21/2020 EPI_ISL_429681 2020-03-16	16/03/2020	<b>Brazil</b>
hCoV-19/Brazil/CV32/2020 EPI_ISL_429688 2020-03-17	17/03/2020	<b>Brazil</b>
hCoV-19/Brazil/CV31/2020 EPI_ISL_429687 2020-03-17	17/03/2020	<b>Brazil</b>
hCoV-19/Brazil/BA-312/2020 EPI_ISL_415105 2020-03-04	04/03/2020	<b>Brazil</b>
hCoV-19/Brazil/SPBR-02/2020 EPI_ISL_413016 2020-02-28	28/02/2020	<b>Brazil</b>
hCoV-19/Brazil/SPBR-10/2020 EPI_ISL_416032 2020-03-04	04/03/2020	<b>Brazil</b>
hCoV-19/Brazil/ES-225/2020 EPI_ISL_415128 2020-02-29	29/02/2020	<b>Brazil</b>
hCoV-19/Brazil/SC-766/2020 EPI_ISL_427305 2020-03-10	10/03/2020	<b>Brazil</b>
hCoV-19/Brazil/SPBR-11/2020 EPI_ISL_416033 2020-03-03	03/03/2020	<b>Brazil</b>
hCoV-19/Brazil/RJ-352/2020 EPI_ISL_427299 2020-03-05	05/03/2020	<b>Brazil</b>
hCoV-19/Brazil/AMBR-02/2020 EPI_ISL_417034 2020-03-16	16/03/2020	<b>Brazil</b>
hCoV-19/Chile/Santiago-2/2020 EPI_ISL_414580 2020-03-05	05/03/2020	<b>Chile</b>
hCoV-19/Chile/Talca-1/2020 EPI_ISL_414577 2020-03-02	02/03/2020	<b>Chile</b>
hCoV-19/Chile/Talca-2/2020 EPI_ISL_414578 2020-03-04	04/03/2020	<b>Chile</b>
hCoV-19/Chile/Santiago-1/2020 EPI_ISL_414579 2020-03-03	03/03/2020	<b>Chile</b>
hCoV-19/Chile/Santiago_op2d1/2020 EPI_ISL_415658 2020-03-06	06/03/2020	<b>Chile</b>
hCoV-19/Chile/Santiago_op3d1/2020 EPI_ISL_415660 2020-03-07	07/03/2020	<b>Chile</b>
hCoV-19/Chile/Santiago_op4d1/2020 EPI_ISL_415661 2020-03-08	08/03/2020	<b>Chile</b>
hCoV-19/Colombia/Antioquia79256/2020 EPI_ISL_417924 2020-03-11	11/03/2020	<b>Colombia</b>
hCoV-19/Costa Rica/06/2020 EPI_ISL_434539 2020-03-25	25/03/2020	<b>Costa Rica</b>
hCoV-19/Costa Rica/02/2020 EPI_ISL_434535 2020-03-16	16/03/2020	<b>Costa Rica</b>
hCoV-19/Costa Rica/04/2020 EPI_ISL_434540 2020-03-18	18/03/2020	<b>Costa Rica</b>
hCoV-19/Costa Rica/05/2020 EPI_ISL_434538 2020-03-20	20/03/2020	<b>Costa Rica</b>
hCoV-19/Costa Rica/01/2020 EPI_ISL_434533 2020-03-16	16/03/2020	<b>Costa Rica</b>
hCoV-19/Peru/010/2020 EPI_ISL_415787 2020-03-10	10/03/2020	<b>Peru</b>

---